跳至主要内容
MedPath Trial logoMedPath TrialMedPath Trial Home
临床试验/LBCTR2024015502
LBCTR2024015502招募中3 期

A PHASE III, RANDOMIZED, OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF GIREDESTRANT IN COMBINATION WITH PHESGO VERSUS PHESGO AFTER INDUCTION THERAPY WITH PHESGO?TAXANE IN PATIENTS WITH PREVIOUSLY UNTREATED HER2-POSITIVE, ESTROGEN RECEPTOR-POSITIVE LOCALLY-ADVANCED OR METASTATIC BREAST CANCER - heredERA

F. Hoffmann-La Roche Ltd0 个研究点目标入组 812 人开始时间: 2024年8月13日最近更新:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
适应症

试验速览

阶段
3 期
状态
招募中
入组人数
812
研究概览研究设计入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomized controlled trial
主要目的
Treatment
盲法
Open (masking not used)

入排标准

年龄范围
18 至 100（—）
性别
All

入选标准

  • •?Signed Informed Consent Form
  • •?Participants (females, regardless of menopausal status, and males) who are aged =18 years at the time of signing Informed Consent Form
  • •- For women: postmenopausal or premenopausal status, defined as follows:
  • •A participant is considered postmenopausal if any of the following definitions are met:
  • •Prior bilateral oophorectomy
  • •Age>60 years
  • •Age <60 years and amenorrheic for 12 months or more in the absence of
  • •chemotherapy or ovarian suppression, and FSH and estradiol in the
  • •postmenopausal ranges
  • •-Pre- or perimenopausal (i.e., not meeting the criteria for postmenopausal)
  • •?Ability to comply with the study protocol, in the investigator’s judgment
  • •Histologically or cytologically confirmed and documented adenocarcinoma of the breast with metastatic or locally-advanced disease not amenable to curative resection.
  • •-HER2-positive ABC confirmed by a central laboratory prior to study enrollment. HER2-positive status will be determined based on primary or metastatic lesion and defined as 3? by immunohistochemistry (IHC) and/or positive by HER2 amplification by in situ hybridization (ISH) with a ratio of = 2 for the number of HER2 gene copies to the number of signals for chromosome 17 copies. Participants will be eligible provided that at least one HER2 test (IHC or ISH) yields a positive result
  • •-A representative formalin-fixed, paraffin-embedded (FFPE) tumor specimen in a paraffin block (preferred) or at least 20 slides containing unstained, freshly cut, serial sections that meet the criteria outlined in Section 8.7 must be submitted prior to study enrollment. In exceptional circumstances, 11-19 slides are acceptable provided that other eligibility requirements are met; however, a minimum of 20 slides is highly preferred. For China, the number of slides required for eligibility will be based on Human Genetics Resources Administration of China (HGRAC) specifications.
  • •-Documented ER-positive tumor according to the American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) guidelines, assessed locally and defined as = 1% of tumor cells staining positive for ER, preferentially based on the same lesion that was used to determine HER2 positivity.
  • •?At least one measurable lesion and/or non-measurable disease evaluable according to RECIST version 1.1
  • •-Note for participants who receive induction therapy off study: baseline tumor assessments must meet the criteria as listed in Section 8.1.1.1 in attached protocol
  • •?Disease-free interval from completion of adjuvant or neoadjuvant systemic non-hormonal treatment to recurrence of = 6 months
  • •?Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or1
  • •?LVEF of at least 50% measured by ECHO or MUGA
  • •?Adequate hematologic and end-organ function, defined by the following laboratory test results, obtained within 7 days prior to enrollment:
  • •- ANC =1.5 x 109 /L (1500 cells/?L) with one exception:
  • •Participants with benign ethnic neutropenia: ANC =1.3?109 /L (1300/?L)
  • •– Platelet count = 100,000 cells/?L
  • •– Hemoglobin =9.0 g/dL
  • •Participants may receive RBC transfusions to obtain this level
  • •– Estimated creatinine clearance = 30mL/min as calculated per institutional guidelines
  • •– INR and aPTT =1.5 ? upper limit of normal (ULN) (except for participants receiving anticoagulation therapy)
  • •For participants receiving warfarin, a stable INR between 2 and 3 is required.
  • •For participants receiving heparin, PTT (or aPTT

排除标准

  • •Potential participants are excluded from the study if any of the following criteria apply:
  • •?Previous systemic non-hormonal anti-cancer therapy in the MBC or ABC setting
  • •Note: Up to one line of single-agent ET given in the metastatic or locallyadvanced setting will be allowed.
  • •One or two cycles of Phesgo (or trastuzumab SC with pertuzumab IV, or PH IV) with docetaxel or paclitaxel in the first line ABC setting is allowed prior to enrollment, provided no limiting toxicities or PD have occurred.
  • •?Previous treatment with approved or investigative anti-HER2 agents except Phesgo (or trastuzumab SC with pertuzumab IV, or PH IV), single-agent trastuzumab IV or SC, ado-trastuzumab emtansine, lapatinib, and neratinib in the neoadjuvant or adjuvant setting
  • •?Disease progression within 6 months of receiving trastuzumab, with or without pertuzumab (IV, SC, or fixed-dose combination), or ado-trastuzumab emtansine in the adjuvant setting
  • •?Non-resolution of all acute toxic effects of prior anti-cancer therapy or surgical procedures to NCI CTCAE v5.0 Grade 1 or better (except alopecia, Grade =2 peripheral neuropathy, or other toxicities that are not considered a safety risk for the participant per investigator's judgment)
  • •? History of persistent Grade = 2 (NCI-CTC, Version 5.0) hematological toxicity resulting from previous adjuvant or neo-adjuvant therapy
  • •? History of exposure to the following cumulative doses of anthracyclines
  • •– Doxorubicin ?360 mg/m2
  • •– Liposomal doxorubicin ?500 mg/m2
  • •– Epirubicin ?720 mg/m2
  • •– Mitoxantrone ?120 mg/m2
  • •– Idarubicin ?90 mg/m2 If another anthracycline or more than one anthracycline has been used, then the cumulative dose must not exceed the equivalent of 360 mg/m2 doxorubicin. (See Appendix 10 in protocol for dose conversions).
  • •?Known active uncontrolled or symptomatic central nervous system (CNS) metastases, carcinomatous meningitis, or leptomeningeal disease
  • •Participants with a history of CNS metastases or cord compression are eligible if they have been definitively treated with local therapy (e.g., radiotherapy, surgery), are clinically stable, and have not been treated with anticonvulsants or corticosteroids within 2 weeks prior to enrollment.
  • •?Dyspnea at rest due to complications of advanced malignancy, or other disease requiring continuous oxygen therapy
  • •?Pregnant or breastfeeding, or intending to become pregnant during the study or within 7 months after the final dose of Phesgo
  • •o Women of childbearing potential must have a negative serum pregnancy test result within 14 days prior to initiation of induction therapy
  • •?Treated with investigational therapy within 28 days prior to initiation of induction therapy · Treated with localized palliative radiotherapy within 14 days prior to initiation of induction therapy
  • •?Concurrent participation in any other therapeutic clinical trial
  • •?Known hypersensitivity to any of the study medications or to excipients of recombinant human or humanized antibodies
  • •?Current chronic daily treatment (continuous for ?3 months) with corticosteroids (dose of 10 mg/day methylprednisolone or equivalent), excluding inhaled steroids
  • •?Poorly controlled hypertension (e.g., systolic blood pressure ?180 mm Hg or diastolic blood pressure ? 100 mmHg)
  • •?Known clinically significant history of liver disease consistent with Child-Pugh Class B or C, active liver disease including active viral or other hepatitis virus (e.g., hepatitis B or hepatitis

研究者

相似试验

招募中
1 期
A clinical trial to compare the effectiveness and safety of giredestrant with a subcutaneous combination of pertuzumab and trastuzumab versus subcutaneous pertuzumab and trastuzumab alone in people with locally advanced or metastatic breast cancer, with HER2 and oestrogen receptor positivity.
CTIS2022-500014-26-00F. Hoffmann-La Roche AG812
招募中
3 期
A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)Cancer
PACTR202212829625733Hoffmann La Roche1,542
尚未招募
3 期
A PHASE III, RANDOMIZED, OPEN-LABEL STUDY EVALUATING EFFICACY AND SAFETY OF GIREDESTRANT COMPARED WITH FULVESTRANT, BOTH COMBINED WITH A CDK4/6 INHIBITOR, IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE, HER2-NEGATIVE ADVANCED BREAST CANCER WITH RESISTANCE TO PRIOR ADJUVANT ENDOCRINE THERAPYC50 Cancer de mama
PER-040-23F. HOFFMANN-LA ROCHE LTD.
招募中
3 期
Clinical trial/study to evaluate safety and efficacy in Breast Cancer patients.
CTRI/2023/08/056489F HoffmannLa Roche Ltd
招募中
1 期
A study to Evaluate Efficacy and Safety of Giredestrant Compared with Fulvestrant (plus a CDK4/6 inhibitor), in Participants with ER+ HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)Estrogen receptor (ER)-positive, HER2-negative advanced breast cancerMedDRA version: 23.0Level: PTClassification code: 10083232Term: HER2 negative breast cancer Class: 100000004864MedDRA version: 21.1Level: LLTClassification code: 10072737Term: Advanced breast cancer Class: 10029104MedDRA version: 23.0Level: LLTClassification code: 10070575Term: Estrogen receptor positive breast cancer Class: 10029104
CTIS2022-502980-39-00F. Hoffmann-La Roche AG1,050